LTR Pharma Receives Ethics Approval for SPONTAN Phase 2 Trial Targeting Elderly Erectile Dysfunction Patients
核心洞察
LTR Pharma (搜索) secured ethics approval from Bellberry Human Research Ethics Committee (搜索) for its SPONTAN (搜索) Phase 2 pharmacokinetic and multiple-dose clinical study, enabling recruitment to begin in Q1 2026.
The randomized crossover trial will recruit approximately 27 healthy male participants across three cohorts, with 50% aged 65 or older to address FDA geriatric use requirements.
The study builds on Phase 1 results showing SPONTAN (搜索) achieved 470% faster absorption than oral tablets, with initial Phase 2 data expected in Q2 2026.
LTR Pharma (搜索) (ASX:LTP) has received Human Research Ethics Committee approval from Bellberry for its SPONTAN (搜索) Phase 2 pharmacokinetic and multiple-dose clinical study, marking a significant advancement in the development of the company's fast-acting intranasal erectile dysfunction (搜索) therapy. The approval clears the way for patient recruitment to commence in the first quarter of 2026.
Study Design and Patient Population
The Phase 2 study has been designed in accordance with FDA Pre-IND guidance to characterize both single and multiple-dose pharmacokinetics of SPONTAN (搜索). The randomized crossover trial will recruit approximately 27 healthy male participants across three cohorts, with approximately 50% of participants aged 65 years or older.
This focus on elderly participants addresses FDA geriatric use requirements and aims to generate prescribing information for older men who are routinely prescribed lower doses of oral PDE5 (搜索) inhibitors such as Viagra due to pharmacokinetic or tolerability factors.
Each participant will complete a 15-day residential period at Scientia Clinical Research (搜索) in Sydney, receiving both single and multiple doses of SPONTAN (搜索) alongside a control vardenafil tablet for comparison.
Clinical Operations and Timeline
Southern Star Research (搜索) has been appointed as the Clinical Research Organisation, with Resolian Bioanalytics (搜索) conducting pharmacokinetic blood sample analysis. Initial data from the study is expected in the second quarter of 2026, with full study results anticipated by mid-2026.
Following the ethics approval, LTR Pharma (搜索) will submit a Clinical Trial Notification to the Therapeutic Goods Administration in Australia, representing a key progression in the company's FDA 505(b)(2) regulatory pathway.
Building on Phase 1 Success
The Phase 2 study builds on LTR Pharma (搜索)'s completed Phase 1 trial, which demonstrated that SPONTAN (搜索) achieved 470% faster absorption compared to oral tablets. The intranasal delivery system is designed to enable onset of action in 10 minutes or less, representing a significant improvement over traditional oral erectile dysfunction (搜索) treatments.
Strategic Commercial Context
LTR Pharma (搜索) Executive Chairman Lee Rodne emphasized the study's importance in the company's broader commercial strategy. "Securing ethics approval allows us to commence a targeted Phase II study expressly designed to meet FDA expectations for multiple-dose pharmacokinetics and geriatric representation," Rodne said. "Importantly, this study will generate valuable data to help physicians make informed prescribing decisions for men aged 65 and older, who often receive reduced-dose oral PDE5 (搜索) therapies."
The SPONTAN (搜索) program operates alongside LTR Pharma (搜索)'s commercialized ROXUS (搜索) therapy, which is on track for US market entry in the first half of 2026. Both products utilize the company's proprietary intranasal drug-delivery platform, which also underpins OROFLOW (搜索), a novel intranasal therapy under development for oesophageal motility disorders (搜索).
Technology Platform and Pipeline
SPONTAN (搜索) is part of LTR Pharma (搜索)'s broader intranasal drug-delivery platform designed to provide rapid-acting treatments for significant unmet medical needs. The company has successfully commercialized its rapid-acting treatment technology in Australia and is expanding access while advancing regulatory pathways in the US and other key markets.
The company's pipeline includes multiple applications of its intranasal delivery technology, with OROFLOW (搜索) representing an expansion into treating oesophageal motility disorders (搜索), a debilitating group of conditions affecting swallowing function.